| Time After Starting | ALT (U/L) | Bilirubin (mg/dL) | HBV DNA (copies/mL) | Other |
|---|---|---|---|---|
| 0 | 524 | 0.9 | 94,500,000 | Liver biopsy |
| 1 month | 210 | 1.1 | 2,430,000 | |
| 2 month | 32 | 1.1 | 2,000 | |
| 12 months | 27 | 1.1 | 100 | |
| 2 years | 20 | 0.9 | <100 | HBeAg negative |
| 4 years | 20 | 0.6 | 200 | Biopsy |
| 5 years | 259 | 1.1 | 157,800,000 | HBeAg positive |
| 5.5 years | 1657 | 1.2 | 59,800,000 | rtM201I mutant |
| 5.8 years | 81 | 1.0 | 37,120,000 | |
| 6.5 years | 101 | 0.6 | 6,670,000 | |
| Lamivudine stopped and tenofovir (300 mg daily) started | ||||
| 7.5 years | 56 | 1.0 | None detected | Still HBeAg positive |
| Normal | <42 | <1.2 | <100 | |
From: Lamivudine
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.